Articles From: AES Announces Philip Odeen Retiring from Board; Charles Rossotti Elected Board Chairman to Aeterna Zentaris to Announce First Quarter 2013 Financial and Operating Results on May 7, 2013 and Hold Annual Shareholders Meeting on May 8, 2013

The AES Corporation (NYSE: AES) today announced that Chairman Philip Odeen has retired from the Board of Directors after 10 years of service.

The AES Corporation (NYSE: AES) announced that it has priced $500 million aggregate principal amount of 4.875% senior notes due 2023 (the “Notes”). AES intends to use the net proceeds from the offering of the Notes, as well as, if necessary, other available funds, to fund concurrent tender offers to purchase for cash certain series of AES’s outstanding senior notes and to pay certain related fees and expenses.

The AES Corporation (NYSE: AES) announced that it has priced an additional $250 million aggregate principal amount of its 4.875% senior notes due 2023 (the “Notes”). The Notes will form a single series with the $500 million aggregate principal amount of 4.875% senior notes due 2023 issued by AES on April 30, 2013 (the "Existing Notes"). AES intends to use the net proceeds from the offering of the Notes and the Existing Notes, as well as, if necessary, other available funds, to fund its previously announced tender offers to purchase for cash certain series of AES’s outstanding senior notes and to pay certain related fees and expenses.

The AES Corporation (“AES”) announced today that it intends, subject to market and other conditions, to offer $500 million aggregate principal amount of senior notes due 2023 (the “Notes”). AES intends to use the net proceeds from the offering of the Notes, as well as, if necessary, other available funds, to fund concurrent tender offers to purchase for cash certain series of AES’s outstanding senior notes and to pay certain related fees and expenses.

The AES Corporation (NYSE: AES) announced today that it intends, subject to market and other conditions, to offer an additional $250 million aggregate principal amount of its 4.875% senior notes due 2023 (the “Notes”). The Notes will form a single series with the $500 million aggregate principal amount of 4.875% senior notes due 2023 issued by AES on April 30, 2013 (the “Existing Notes”). AES intends to use the net proceeds from the offering of the Notes and the Existing Notes, as well as, if necessary, other available funds, to fund its previously announced tender offers to purchase for cash certain series of AES’s outstanding senior notes and to pay certain related fees and expenses.

The Board of Directors of The AES Corporation (NYSE:AES) declared a quarterly common stock dividend of 4 cents per share payable May 15, 2013 to shareholders of record at the close of business on May 1, 2013.

The AES Corporation (“AES”) announced today the commencement of tender offers to purchase (each offer a “Tender Offer” and collectively, the “Tender Offers”) for cash, subject to certain terms and conditions, any and all of its outstanding 7.75% senior notes due 2014 (the “2014 Notes”), and up to a total of $300 million aggregate principal amount of its outstanding 7.75% senior notes due 2015 (the “2015 Notes”), 9.75% senior notes due 2016 (the “2016 Notes”), and 8.00% senior notes due 2017 (the “2017 Notes” and, together with the 2014 Notes, the 2015 Notes and the 2016 Notes, the “Securities”), subject to the Series Maximum Tender Amount (set forth in the table below) for each of the 2015 Notes, 2016 Notes and 2017 Notes (collectively, the “Capped Securities”). The Tender Offers are scheduled to expire at 11:59 p.m., New York City time, on May 22, 2013 (the “Expiration

The AES Corporation (NYSE: AES) announced today the early results of its previously announced tender offers to purchase (each offer a “Tender Offer” and collectively, the “Tender Offers”) for cash, subject to certain terms and conditions, its outstanding 7.75% Senior Notes due 2014 (the “2014 Notes”), 7.75% Senior Notes due 2015 (the “2015 Notes”), 9.75% Senior Notes due 2016 (the “2016 Notes”) and 8.00% Senior Notes due 2017 (the “2017 Notes” and, together with the 2014 Notes, the 2015 Notes and the 2016 Notes, the “Securities”). On April 25, 2013, AES commenced the Tender Offers to purchase the Securities in accordance with the terms and conditions set forth in the Offers to Purchase for Cash and related Letter of Transmittal (collectively, the “Tender Offer Materials”). The Tender Offers will expire at 11:59 p.m., New York City time, on May 22, 2013 (the “Expiration Date”), unless

AES today announced a milestone in the energy storage industry as its AES Laurel Mountain facility surpassed the 400,000 MW-h mark of regulation service to the PJM Interconnection.

Today, The AES Corporation (NYSE: AES) posted a new presentation to its website at approximately 8:00 AM Eastern Standard Time, in connection with investor meetings.

In connection with the senior notes offering and tender offers announced today, The AES Corporation (NYSE: AES) reaffirmed full year 2013 guidance and provided preliminary Adjusted Earnings Per Share (Adjusted EPS, a non-GAAP financial measure) results of $0.25-$0.27 for first quarter 2013.

The AES Corporation (NYSE: AES) today reported Adjusted Earnings Per Share (Adjusted EPS, a non-GAAP financial measure) of $1.24 for full year 2012.

The AES Corporation (NYSE: AES) today reported Adjusted Earnings Per Share (Adjusted EPS, a non-GAAP financial measure) of $0.26 for first quarter 2013, a decline of $0.11 from first quarter 2012.

The AES Corporation (NYSE: AES) will webcast its investor day on May 9, 2013 at 8:00 AM Eastern Daylight Time (EDT). At the event, AES Management will deliver prepared remarks, including a review of its first quarter 2013 results, and host a question and answer session with analysts and investors.

Aeterna Zentaris and Ergomed Sign Co-Development and Profit Sharing Agreement for AEZS-108 in Endometrial Cancer Canada NewsWire All amounts are in US dollars QUÉBEC CITY, April 10, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the signing of a co-development and profit sharing agreement with Ergomed Clinical Research Ltd.

All amounts are in US dollars QUÉBEC CITY, April 10, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the signing of a co-development and profit sharing agreement with Ergomed Clinical Research Ltd.

Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders Canada NewsWire QUÉBEC CITY, May 8, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announces the results of the vote on directors held earlier today at its annual meeting of shareholders.

QUÉBEC CITY, May 8, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announces the results of the vote on directors held earlier today at its annual meeting of shareholders.

Aeterna Zentaris Announces Transfer of Manufacturing Rights Related to Cetrotide® to Merck KGaA Canada NewsWire All amounts are in US dollars (unless otherwise mentioned) QUÉBEC CITY, April 17, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide ® product.

All amounts are in US dollars (unless otherwise mentioned) QUÉBEC CITY, April 17, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide ® product.

Aeterna Zentaris Newly Appointed CEO, David A.

QUEBEC CITY , April 23, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") newly appointed President and CEO, David A.

Aeterna Zentaris Presents Encouraging Updated Data on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at AACR Meeting Canada NewsWire QUÉBEC CITY, April 10, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today presented encouraging updated proof-of-concept results for Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138, in human ovarian and endometrial cancer xenograft models.

QUÉBEC CITY, April 10, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today presented encouraging updated proof-of-concept results for Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138, in human ovarian and endometrial cancer xenograft models.

All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, May 7, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late‑stage drug development company specializing in oncology and endocrinology, today reported financial and operating results as at and for the first quarter ended March 31, 2013 .

Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results Canada NewsWire All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, May 7, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late‑stage drug development company specializing in oncology and endocrinology, today reported financial and operating results as at and for the first quarter ended March 31, 2013 .

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2012 Financial and Operating Results Canada NewsWire All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, March 21, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage drug development company specializing in oncology and endocrinology, today reported financial and operating results as at and for the fourth quarter and the year ended December 31, 2012 .

All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, March 21, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage drug development company specializing in oncology and endocrinology, today reported financial and operating results as at and for the fourth quarter and the year ended December 31, 2012 .

Aeterna Zentaris to Announce First Quarter 2013 Financial and Operating Results on May 7, 2013 and Hold Annual Shareholders Meeting on May 8, 2013 Canada NewsWire QUEBEC CITY, May 1, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its first quarter 2013 financial and operating results after market close on Tuesday, May 7, 2013 .

QUEBEC CITY , May 1, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its first quarter 2013 financial and operating results after market close on Tuesday, May 7, 2013 .